Antipsychotic use in pregnancy and the risk for congenital malformations

JAMA Psychiatry

Volumn 73, Issue 9, 2016, Pages 938-946

  Huybrechts, Krista F ^a   Hernández Díaz, Sonia ^b   Patorno, Elisabetta ^a   Desai, Rishi J ^a   Mogun, Helen ^a   Dejene, Sara Z ^a   Cohen, Jacqueline M ^b   Panchaud, Alice ^b   Cohen, Lee ^a,c   Bateman, Brian T ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; NORMAL HUMAN; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; ABNORMALITIES, DRUG-INDUCED; CHEMICALLY INDUCED; HEART DEFECTS, CONGENITAL; MEDICAID; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOTIC DISORDERS; RISK; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT, NEWBORN; MEDICAID; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PSYCHOTIC DISORDERS; RISK; RISPERIDONE; UNITED STATES; YOUNG ADULT;

EID: 84996635716     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2016.1520     Document Type: Article

References (17)

1. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. J Clin Psychiatry. 2005;66(4):444-449.
2. Mitchell AA, Gilboa SM,Werler MM, Kelley KE, Louik C, Hernández-Díaz S; National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011;205 (1):51.e1-51.e8.
3. Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother. 2004;38(7-8):1265-1271.
4. Kulkarni J,Worsley R, Gilbert H, et al. A prospective cohort study of antipsychotic medications in pregnancy: The first 147 pregnancies and 100 one year old babies. PLoS One. 2014;9(5): e94788.
5. Cohen LS, Viguera AC, McInerney KA, et al. Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Am J Psychiatry. 2016;173(3):263-270.
6. Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28(3):279-288.
7. Habermann F, Fritzsche J, Fuhlbrück F, et al. Atypical antipsychotic drugs and pregnancy outcome: A prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453-462.
8. Palmsten K, Huybrechts KF, Mogun H, et al. Harnessing the Medicaid Analytic Extract (MAX) to evaluate medications in pregnancy: design considerations. PLoS One. 2013;8(6):e67405.
9. Centers for Medicare & Medicaid Services. Medicaid Analytic Extract (MAX) general information: MAX 1999-2005 state claims anomalies from the "2005 Files" zipped file within the MAX Data 2005 to 2008 General Information, Data Dictionaries, Data Element Lists, Data Anomalies, Validation Table Measures and SAS Loads zipped file. https://www.cms.gov/Research-Statistics-Data-and-Systems/Computer-Data-and-Systems/MedicaidDataSourcesGenInfo/MAXGeneralInformation.html. Accessed December 22, 2014.
10. Bateman BT,Mhyre JM, Hernández-Díaz S, et al. Development of a comorbidity index for use in obstetric patients. Obstet Gynecol. 2013;122(5): 957-965.
11. Schneeweiss S, Seeger JD, Maclure M,Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154 (9):854-864.
12. Desai R, Rothman K, Bateman B, Hernández-Díaz S, Huybrechts K. Confounding control using propensity scores when the exposure is infrequent: making the case for a fine stratification approach. Pharmacoepidemiol Drug Saf. 2015;24(24)(suppl 1):217.
13. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, BrookhartMA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512-522.
14. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397-2407.
15. Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations: A systematic review. Basic Clin Pharmacol Toxicol. 2015;116(4): 315-320.
16. Bateman BT, Hernández-Díaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ. 2015;350:h1035.
17. Palmsten K, Huybrechts KF, Kowal MK, Mogun H, Hernández-Díaz S. Validity of maternal and infant outcomes within nationwide Medicaid data. Pharmacoepidemiol Drug Saf. 2014;23(6):646-655.